### Marketing of oral artemisinin-based monotherapy medicines at country level

(Last updated on 24 October 2017)

#### National health authorities taking regulatory measures against the marketing of oral artemisinin-based monotherapies (oAMTs)

<table>
<thead>
<tr>
<th>22 national health authorities</th>
<th>51 national health authorities</th>
<th>5 national health authorities</th>
</tr>
</thead>
<tbody>
<tr>
<td>have never registered oAMTs</td>
<td>have taken regulatory measures to withdraw the marketing authorization of oAMTs</td>
<td>still allow the marketing of oAMTs for the treatment of uncomplicated malaria</td>
</tr>
</tbody>
</table>

- Afghanistan
- Botswana
- Brazil
- Djibouti
- Ecuador
- Eritrea
- Ethiopia
- Indonesia
- Iran
- Malaysia
- Nepal
- Peru
- Philippines
- Saudi Arabia
- South Africa
- Sri Lanka
- Suriname
- Tajikistan
- Timor Leste
- Vanuatu
- Venezuela
- Zimbabwe
- Bangladesh
- Benin
- Bhutan
- Bolivia
- Burkina Faso
- Burundi
- Cambodia
- Cameroon
- Central African Republic
- Chad
- China
- Colombia
- Comoros
- Congo
- Côte d'Ivoire
- Democratic Republic of Congo
- Gabon
- Ghana
- Guinea
- Guinea-Bissau
- Guyana
- India
- Kenya
- Lao People's Democratic Republic
- Liberia
- Madagascar
- Mali
- Mauritania
- Mozambique
- Myanmar
- Namibia
- Niger
- Nigeria
- Pakistan
- Papua New Guinea
- Rwanda
- Sao Tome Principe
- Senegal
- Sierra Leone
- Solomon Islands
- Sudan
- Tanzania
- Thailand
- Togo
- Uganda
- Viet Nam
- Yemen
- Zambia
- Zanzibar (United Republic of Tanzania)
- Angola
- Cape Verde
- Gambia
- Somalia
- Swaziland